Philogen SpA
78Q
Company Profile
Business description
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
Contact
Piazza La Lizza No. 7
Siena53100
ITAT: +39 57717816
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
214
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,958.80 | 53.30 | -0.59% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,313.04 | 313.24 | -1.18% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,343.09 | 490.75 | -0.78% |
| NZX 50 Index | 13,174.17 | 96.44 | -0.73% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,724.90 | 55.90 | -0.64% |
| SSE Composite Index | 4,162.27 | 17.82 | -0.43% |